The ownership of CRISPR technology is complex and involves multiple entities, including universities, research institutions, and companies.
Key Players in CRISPR Ownership:
- The Broad Institute: Holds patents for CRISPR-Cas9 technology, specifically for its use in eukaryotic cells, including human cells. This patent is heavily contested by the University of California, Berkeley.
- The University of California, Berkeley: Holds patents for CRISPR-Cas9 technology, specifically for its use in prokaryotic cells (bacteria and archaea). This patent is heavily contested by the Broad Institute.
- Intellia Therapeutics: A company focused on developing CRISPR-based therapies for a variety of diseases. They have a licensing agreement with the Broad Institute for their CRISPR technology.
- Editas Medicine: A company focused on developing CRISPR-based therapies for rare genetic diseases. They have a licensing agreement with the University of California, Berkeley for their CRISPR technology.
- CRISPR Therapeutics: A company focused on developing CRISPR-based therapies for blood disorders and other diseases. They have licensing agreements with both the Broad Institute and the University of California, Berkeley for their CRISPR technology.
Ongoing Legal Disputes:
The ownership of CRISPR technology is currently the subject of ongoing legal disputes between the Broad Institute and the University of California, Berkeley. The outcome of these disputes will have a significant impact on the future of CRISPR technology development and commercialization.
Future of CRISPR Ownership:
The future of CRISPR ownership is uncertain, but it is likely that the technology will be used by a wide range of companies and research institutions. The ongoing legal disputes may lead to a more complex licensing landscape, but it is also possible that a more collaborative approach to CRISPR development will emerge.
